TTNP - Wutah dodolan YoY (TTM) titanpharm.com

Logo grafis titanpharm.com (TTNP)

Titan Pharmaceuticals relies on the expertise of biochemists in developing extended-release drug delivery systems. However, litigation and a shortage of funds for innovation create serious risks. The rolling 12-month revenue growth trend on the GURU.Markets chart visualizes this crisis, where -46.40 shows the value of this parameter. Currently, the company lacks pricing power and is seeking ways to survive amid restructuring.

Titan Pharmaceuticals (TTNP) - Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 20.02.2024

Titan Pharmaceuticals (TTNP) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:TTNP (Titan Pharmaceuticals, Inc.)
Produk dadi Titan Pharma

Portfolio managers evaluate the operating model of Titan Pharmaceuticals (TTNP) through revenue dynamics over the last 12 months, calculated via a daily comparison of current annual turnover against the same period last year to eliminate accounting distortions. By analyzing the TTM revenue growth trajectory compared to the previous year, an investor can gauge the real effectiveness of licensing agreements and the stability of partnerships within the drug delivery systems sector.